Calyx IPO test India investors’ appetite for CRAMS
This article was originally published in Scrip
Executive Summary
Just a few days after Arch Pharmalabs announced its initial public offering on the Indian stock market (scripintelligence.com, 31 March 2011), a second contract research and manufacturing services (CRAMS) firm, Calyx Chemicals and Pharmaceuticals has announced its own plans for an initial public offering (IPO). The uptake of newly issued Arch and Calyx stock will test investor enthusiasm for service offerings in the Indian pharmaceutical sector.